Articles · Retatrutide
Stop pinning your retatrutide in your stomach: why rotating injection sites matters
"Stop pinning your retta in your stomach" is one of my most-watched reels this month, and the comments told me why. A lot of people think the lower stomach is the only place a subcutaneous peptide can go. It isn't. If you're getting lean, or you're noticing lumps and welts where you inject, you have options. Here's the reasoning behind the reel, and the research that backs it up.
Why everyone defaults to the stomach
The abdomen is the easiest spot to reach, it usually has the most fat to pinch, and it's the site most people are shown first. Retatrutide is given as a subcutaneous injection, into the fat layer under the skin, the same way it was given in the phase 2 obesity trial.[6] Nothing about that requires the stomach specifically. The stomach is just a habit.
The problem is what happens when you use the same small patch of skin over and over.
The real problem: scar tissue and lumps
Repeated injections into one area can cause lipohypertrophy: a thickened, rubbery or lumpy area of fat under the skin. Most of what we know about it comes from people with diabetes who inject insulin every day, because they've been doing it for decades and researchers have studied it closely.
The numbers are striking. In a 2013 study of 430 people injecting insulin, nearly two-thirds had lipohypertrophy when a nurse examined their injection sites. Rotation was the deciding factor. Of the people who rotated correctly, only 5% had it. Of the people who had it, 98% either didn't rotate at all or rotated incorrectly. Reusing needles more than five times also raised the risk.[1]
Why lumpy tissue matters for absorption
This isn't just cosmetic. A 2016 crossover study in Diabetes Care injected the same insulin into lipohypertrophic tissue and into normal fat in the same people. Injections into the lumpy tissue were absorbed less, had a weaker effect, and were far less predictable from one injection to the next. Variability in absorption jumped from about 11% in normal tissue to 52% in the affected tissue.[2]
That study was on insulin, not retatrutide, so I'm not going to pretend it's a direct measurement for your peptide. But the principle is the same for anything you inject under the skin: damaged tissue is a worse place to put it. International injection guidelines say it plainly: don't inject into these lesions, and rotate sites to prevent them.[3]
Getting lean changes the math
Here's the other half of my reel. As you lose fat, the layer you're pinching on your stomach gets thinner. The same expert guidelines recommend short needles and warn against accidentally going into muscle, because intramuscular injection changes how a drug is absorbed.[3] If your lower stomach doesn't have much left to pinch, it makes sense to look at other areas with more subcutaneous fat.
Your other options
In the reel I list the glutes, the hip, the back of the arm and the thigh. Spreading injections across several areas gives each patch of skin time to recover instead of building up scar tissue in one place.
My personal favorite is the glutes. There's more surface area and it's easier to find a fresh spot every time. One honest note: the approved GLP-1 class pens are labeled for the abdomen, thigh and upper arm, and those are the sites the comparison studies below tested. The glutes and hip are common subcutaneous sites too, they just weren't part of those studies.
Does the site change how strong it is?
This is the question I get the most, and the short answer is no. Researchers have tested exactly this for drugs in the same family as retatrutide. In a 2005 crossover study, exenatide injected into the arm or thigh was absorbed about the same as when it was injected into the abdomen, with the totals falling inside standard equivalence limits.[4] For dulaglutide, a once-weekly GLP-1 drug, the clinical pharmacokinetic analysis found no difference between the arm, thigh and abdomen, and concluded no dose adjustment was needed based on site.[5]
Retatrutide hasn't had its own published site-comparison study yet. But it's a once-weekly peptide in the same incretin family, and the consistent finding across that family is that healthy subcutaneous fat is healthy subcutaneous fat. What actually hurts absorption is injecting into damaged tissue, which is exactly what rotating prevents.[2]
A simple rotation habit
Pick a few areas and move through them in order, and inside each area, keep each injection a little away from the last one. Use a fresh needle every time. Check your usual spots with your fingers every so often: if something feels thick, rubbery or lumpy, skip it and let it recover. If you notice a reaction that doesn't settle, bring it up with your clinician.
The takeaway
You don't have to pin your stomach. Rotating across areas protects your tissue, keeps absorption more predictable, and gives you more room to work with as you get leaner. The site doesn't make your peptide weaker. Damaged tissue does. For more on starting out, read the retatrutide mistakes I see beginners make.
Want a plan built around your goals? Join The Peptide Lab coaching.
References
- Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013. PubMed 23886784
- Famulla S, et al. Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control. Diabetes Care. 2016. PubMed 27411698
- Frid AH, et al. New Insulin Delivery Recommendations. Mayo Clin Proc. 2016. PubMed 27594187
- Calara F, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther. 2005. PubMed 15811484
- Geiser JS, et al. Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Clin Pharmacokinet. 2016. PubMed 26507721
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023. PubMed 37366315